中国当代医药2026，Vol.33Issue(5)：84-88,5.DOI:10.3969/j.issn.1674-4721.2026.05.17
甲状腺乳头状癌患者BRAF V600E基因突变与临床病理参数的相关性分析
Association between BRAF V600E mutation and clinicopathological pa-rameters in patients with papillary thyroid carcinoma
摘要
Abstract
Objective To investigate the correlation between the BRAF V600E mutation and clinicopathological parameters in patients with papillary thyroid carcinoma(PTC),providing a basis for precision diagnosis and treatment.Methods A total of 213 PTC patients admitted to Dongguan Kanghua Hospital from January to December 2023 were selected as the study subjects.Based on the presence or absence of BRAF V600E gene mutation,they were divided into mutation group(128 cases)and non-mutation group(85 cases).The relationship between mutation status and factors such as gender,age,ultrasound features,surgical pathological parameters(maximum tumor diameter,extrathyroidal extension,lymph node metastasis),Thyroid Imaging Reporting and Data System(TIRADS)classification,as well as thyroid-stimulating hormone and thyroglobulin levels were analyzed.Results The maximum nodule diameter,maximum tumor diameter,thyroid stimu-lating hormone,and thyroglobulin levels in the mutation group were higher than those in the non-mutation group,with statistical significances(P＜0.05).The proportion of TIRADS category 4 and above,the rate of extrathyroidal extension,and the rate of lymph node metastasis in the mutation group were higher than those in the non-mutation group,with statistical significances(P＜0.05).Spearman correlation analysis revealed positive correlations between the BRAF V600E mutation and the aforementioned parameters(P＜0.05).Multivariate logistic regression analysis further identified TIRADS category 4 and above,lymph node metastasis,and higher thyroglobulin level were independent influencing factors for the BRAF V600E mutation.Conclusion The BRAF V600E mutation is highly prevalent in PTC and is significantly associated with aggressive pathological features and abnormal thyroid function indices.TIRADS high-grade classification,lymph node metastasis,and elevated thyroglobulin level are independent predictors of this mutation.BRAF V600E testing can serve as a crucial biomarker for assessing tumor malignancy and guiding in-dividualized treatment strategies.关键词
甲状腺乳头状癌/BRAF V600E突变/临床病理参数/超声特征/淋巴结转移Key words
Papillary thyroid carcinoma/BRAF V600E mutation/Clinicopathological parameters/Ultrasonic characteristics/Lymph node metastasis分类
医药卫生引用本文复制引用
梁爱芬,何韶坚,金韬,吴敏君,李润涛,隋洪..甲状腺乳头状癌患者BRAF V600E基因突变与临床病理参数的相关性分析[J].中国当代医药,2026,33(5):84-88,5.基金项目
广东省医学科学技术研究基金项目(B2024140). （B2024140）
